Document:

Exhibit

Exhibit 10.9.7

UK SUB-PLAN
under the 
ACCELERATE DIAGNOSTICS, INC.
2012 OMNIBUS EQUITY INCENTIVE PLAN

This UK Sub-Plan, adopted under the 2012 Accelerate Diagnostics, Inc. Omnibus Equity Incentive Plan (the “Plan”), is effective as of September 14, 2018.  To the extent not specifically defined in this Sub-Plan, all capitalized terms used in this Sub-Plan shall have the meaning set forth in the Plan.

		
	1.
	Purpose.  The primary purpose of this Sub-Plan is to amend those provisions of the Plan which are required to be amended in order for awards made under the Plan, and communications concerning those awards, to be exempt from provisions of the United Kingdom Financial Services and Markets Act 2000 (the “FSMA”).

		
	2.
	Application.  This Sub-Plan shall be used solely to grant awards to employees of the Company or any member of the same Group as the Company resident and providing services in the United Kingdom.  For this purpose, the term “Group” in relation to the Company shall have the meaning given to such term in Section 421 of the FSMA.

		
	3.
	Restricted Delivery of Awards.  The settlement of awards under this Sub-Plan shall be made only in shares of Stock or such other securities of the Company that may arise from such shares of Stock under the adjustment provisions of the Plan.  For the avoidance of doubt, and without limitation, no cash settlement of awards (including dividends or dividend equivalent payments in cash) shall be permissible.

		
	4.
	Exercise of Options/Vesting of Awards.  The Administrator may specify, in its discretion, any other conditions of exercise and/or vesting of awards that will be specified in the Award Agreement.

		
	5.
	Restricted Transfer of Rights.  The persons to whom rights under any award may be assigned or transferred, whether by will or the laws of descent and distribution or the transferability of awards shall be limited to a Participant's children and step-children under the age of eighteen, spouses and surviving spouses and civil partners and civil partners (within the meaning of the United Kingdom Civil Partnerships Act 2004) and surviving partners.

		
	6.
	Tax.  All awards will be subject to tax withholding but, for the purposes of this Sub-Plan, references to “tax” shall be read and construed as including, without limitation, United Kingdom income tax and primary class 1 (employee’s) national insurance contributions that the Participant’s employer is liable to account for and, if so agreed between the Company and the Participant, secondary class 1 (employer’s) national insurance contributions that the Participant’s employer is liable to account for.

		
	7.
	Incorporation of Plan Provisions.  The provisions of the Plan shall apply to all awards made under this Sub-Plan and shall accordingly be deemed to be incorporated herein, save as varied by the terms of this Sub-Plan.

IN WITNESS WHEREOF, the Company has caused this Fourth Amendment to be executed as of this 14th day of September, 2018.

	
	
	ACCELERATE DIAGNOSTICS, INC.

	/s/ Steve Reichling

	Steve Reichling
Chief Financial OfficerEXHIBIT 10.3

PATENT LICENSE AGREEMENT

 

 

THIS AGREEMENT is
made as of this by and between Charles Scott, an individual, located at 3321 Beechcliff Ln., Alexandria, VA 22306, Survicore
Financial Holdings, Inc., a Nevada Corporation, having an address at 107 Southwest St. PMB 557, Alexandria, VA 22314 (collectively
LICENSOR), and Clinical & Herbal Innovations., Inc, a Georgia corporation, with offices at 206 N. Washington St #100, Alexandria,
VA 22314 (LICENSEE) (collectively the “PARTIES”).

 

W I T N E S S E T H:

 

WHEREAS, LICENSOR is the sole and exclusive
owner of United States Letters Patents identified more fully in the attached Schedule A (collectively, the “Patents”);
and

 

WHEREAS, LICENSEE desires to acquire a nonexclusive
and nontransferable license under the Patents for use in the development and sale of the types of products listed in the attached
Schedule A (the “Licensed Products”);

 

WHEREAS, LICENSOR has the power and authority
to grant to LICENSEE such license.

 

NOW, THEREFORE, in
consideration of the mutual promises and covenants herein contained, the parties hereto agree as follows:

 

1. LICENSE

A. LICENSOR hereby grants to LICENSEE, upon
and subject to all the terms and conditions of this Agreement, a nonexclusive license under the Patents to make, use, and sell
the systems and methods embodying the invention(s) described in the Patents, for the life of such Patents, in the Licensed Territory,
as set forth in the attached Schedule A. The LICENSE shall commence as immediately upon the satisfaction of the terms and conditions
are met as specified in Section 3 (COMPENSATION) of this Agreement, and no sooner.

 

B. As used in the Agreement, the Patents shall
mean and include the United States Letters Patents, Philippines Patent and Pending Canadian Patent application and any subsequent
patent grants of same, identified more fully in the attached Schedule A, along with any patents on improvements thereof. In addition,
the Patents shall mean and include the following:

 

1. Any divisional, continuation, or substitute
patent applications that shall be based on the patents and application listed in Schedule A; and

 

2. Any patents that shall issue on any of the
above-described patent applications or on any improvements thereof, and any reissues and extensions thereof.

 

C. The license granted herein is subject to
a reserved, nonexclusive, nonassignable license in LICENSOR to make, use, and sell the products embodying the invention(s) of the
Patents.

 

    	1 of 7

    	 

    

 

D. LICENSEE may not grant sublicenses under
this agreement.

 

E. LICENSOR may grant an unlimited number of
nonexclusive licenses to other parties no a party to this agreement.

 

2. TERM

This Agreement shall be effective as of the
date of execution by the Parties and shall expire on December 31st, 2023 at 11:59PM Eastern Standard US time, unless sooner terminated
by the Parties pursuant to the terms of this Agreement (the Term).

 

3. COMPENSATION

A. In consideration for the licenses granted
hereunder, LICENSEE agrees to pay LICENSOR all due compensation and bonuses in full as they come due under a separate agreement.
The company must satisfy any and all outstanding obligations to LICENSOR under that certain other agreement.

 

4. RECORD INSPECTION AND AUDIT

A. LICENSOR shall have the right, upon reasonable
notice, to inspect LICENSEE’s books and records and all other documents and material in LICENSEE’s possession or control
with respect to the subject matter of this Agreement. LICENSOR shall have free and full access thereto for such purposes and may
make copies thereof. In no event shall LICENSOR have the right to examine information with respect to LICENSEE’s costs, pricing
formulas, or percentages of markup. LICENSEE shall impose similar obligations on its sublicensees for the benefit of itself and
of LICENSOR.

 

B. In the event that such inspection reveals
an underpayment by LICENSEE of the actual Royalty owed LICENSOR, LICENSEE shall pay the difference, plus interest calculated at
the rate of [Number] Percent ([#] %) per month. If such underpayment be in excess of [Number] Dollars ($[#])
for any Royalty Period, LICENSEE shall also reimburse LICENSOR for the cost of such inspection.

 

C. All books and records relative to LICENSEE’s
obligations hereunder shall be maintained and made accessible to LICENSOR for inspection at a location in the United States for
at least [number] years after termination of this Agreement.

 

5. INTELLECTUAL PROPERTY PROTECTION

A. In the event that LICENSEE wishes that a
corresponding patent application of any other country, territory, or possession be filed, it shall notify LICENSOR of that wish,
and LICENSOR shall thereupon promptly notify LICENSEE whether it will file such other patent application. Failing such agreement,
LICENSOR shall at LICENSEE’s notification permit LICENSEE to file such patent application and prosecute it to issuance or
final rejection at its own expense. Such patent application, any patent issuing thereon, and any renewals and extensions thereof
shall be added to the aforesaid Patents, and LICENSOR shall have the title thereto.

 

B. With the exception of patent applications
filed by LICENSEE, all patent applications comprised within the Patents shall be prosecuted to issuance or final rejection by LICENSOR
at LICENSEE’s cost and expense. 

    	2 of 7

    	 

    

 

Any taxes, annuities, working fees, maintenance fees, and/or renewal and extension charges
with respect to each patent application and patent subject to this Agreement shall be punctually paid by LICENSEE.

 

6. WARRANTIES AND OBLIGATIONS

A. LICENSOR represents and warrants that, to
the best of its knowledge and belief it is the owner of the entire right, title, and interest in and to the Patents; that it has
the right and power to grant the licenses granted herein; that there are no other agreements with any other party in conflict with
such grant; and that it knows of no prior art that would invalidate the Patents.

 

B. LICENSOR further represents and warrants
that, to the best of its knowledge and belief, LICENSEE’s contemplated use of the Patents as represented to LICENSOR does
not infringe any valid rights of any third party, and that there are no actions for infringement against LICENSOR with respect
to items it manufactures and sells embodying the invention of the Patents anywhere in the world.

 

C. LICENSEE shall be solely responsible for
the manufacture, production, sale, and distribution of the Licensed Products and will bear all costs associated therewith.

 

7. MARKING AND SAMPLES

A. LICENSEE shall fully comply with the patent
marking provisions of the intellectual property laws of the applicable countries in the Licensed Territory.

 

B. At least once during each calendar year,
LICENSEE shall submit to LICENSOR samples of each of the Licensed Products.

 

8. TERMINATION

The following termination rights are in addition
to the termination rights that may be provided elsewhere in the Agreement:

 

A. Immediate Right of Termination. LICENSOR
shall have the right to immediately terminate this Agreement by giving written notice to LICENSEE in the event that LICENSEE does
any of the following:

 

1. Fails to obtain or maintain product liability
insurance in the amount and of the type provided for herein;

 

2. Files a petition in bankruptcy or is adjudicated
a bankrupt or insolvent, or makes an assignment for the benefit of creditors or an arrangement pursuant to any bankruptcy law,
or if the LICENSEE discontinues or dissolves its business or if a receiver is appointed for LICENSEE or for LICENSEE’s business
and such receiver is not discharged within 5 days;

 

B. Right to Terminate Upon Notice. Either
party may terminate this Agreement upon 3 days’ written notice to the other party in the event of a breach of any provision
of this Agreement by the other party, provided that, during the 3-day period, the breaching party fails to cure such breach.

 

    	3 of 7

    	 

    

 

C. LICENSEE Right to Terminate. LICENSEE
shall have the right to terminate this Agreement at any time upon 3 days’ written notice to LICENSOR, such termination to
become effective at the conclusion of such 3-day period.

 

9. POST TERMINATION RIGHTS

Upon expiration or termination of this Agreement,
LICENSEE shall thereafter immediately, except for reason of termination because of expiration or a declaration of patent invalidity,
cease all further use of the Patents and all rights granted to LICENSEE under this Agreement shall forthwith terminate and immediately
revert to LICENSOR.

 

10. INFRINGEMENTS

A. LICENSOR shall have the sole and exclusive
right, in its discretion, to institute and prosecute lawsuits against third persons for infringement of the rights licensed in
this Agreement. All sums recovered in any such lawsuits, whether by judgment, settlement or otherwise, in excess of the amount
of reasonable attorneys’ fees and other out of pocket expenses of such suit, shall be retained solely by LICENSOR.

 

B. LICENSEE agrees to fully cooperate with
LICENSOR in the prosecution of any such suit against a third party and shall execute all papers, testify on all matters, and otherwise
cooperate in every way necessary and desirable for the prosecution of any such lawsuit. The LICENSOR shall reimburse the LICENSEE
for any expenses incurred as a result of such cooperation.

 

11. CONFIDENTIALITY 

A. “Confidential Information” shall
mean any confidential technical data, trade secret, know-how or other confidential information disclosed by any party hereunder
in writing, orally, or by drawing or other form and which shall be marked by the disclosing party as “Confidential”
or “Proprietary.” If such information is disclosed orally, or through demonstration,
in order to be deemed Confidential Information, it must be specifically designated as being of a confidential nature at the time
of disclosure and reduced in writing and delivered to the receiving party within [number] ([#]) days of such disclosure.

 

B. Notwithstanding the foregoing, Confidential
Information shall not include information which: (i) is known to the receiving party at the time of disclosure or becomes known
to the receiving party without breach of this Agreement; (ii) is or becomes publicly known through no wrongful act of the receiving
party or any subsidiary of the receiving party; (iii) is rightfully received from a third party without restriction on disclosure;
(iv) is independently developed by the receiving party or any of its subsidiary; (v) is furnished to any third party by the disclosing
party without restriction on its disclosure; (vi) is approved for release upon a prior written consent of the disclosing party;
(vii) is disclosed pursuant to judicial order, requirement of a governmental agency or by operation of law.

 

C. The receiving party agrees that it will
not disclose any Confidential Information to any third party and will not use Confidential Information of the disclosing party
for any purpose other than for the performance of the rights and obligations hereunder during the term of this Agreement, without
the prior written consent of the disclosing 

    	4 of 7

    	 

    

 

party. The receiving party further agrees that Confidential Information shall remain
the sole property of the disclosing party and that it will take all reasonable precautions to prevent any unauthorized disclosure
of Confidential Information by its employees. No license shall be granted by the disclosing party to the receiving party with respect
to Confidential Information disclosed hereunder unless otherwise expressly provided herein.

 

D. Upon the request of the disclosing party,
the receiving party will promptly return all Confidential information furnished hereunder and all copies thereof.

 

E. The Parties agree that all publicity and
public announcements concerning the formation and existence of this Agreement shall be jointly planned and coordinated by and among
the Parties. Neither party shall disclose any of the specific terms of this Agreement to any third party without the prior written
consent of the other party, which consent shall not be withheld unreasonably. Notwithstanding the foregoing, any party may disclose
information concerning this Agreement as required by the rules, orders, regulations, subpoenas or directives of a court, government
or governmental agency, after giving prior notice to the other party.

 

F. If a party breaches any
of its obligations with respect to confidentiality and unauthorized use of Confidential information hereunder, the non-breaching
party shall be entitled to equitable relief to protect its interest therein, including but not limited to injunctive relief, as
well as money damages notwithstanding anything to the contrary contained herein.

 

G. Except as otherwise set forth in this Agreement,
neither party will make any public statement, press release or other announcement relating to the terms of or existence of this
Agreement without the prior written approval of the other.

 

12. INDEMNITY

A. LICENSEE agrees to defend, indemnify and
hold LICENSOR and its officers, directors, agents, and employees, harmless against all costs, expenses, and losses (including reasonable
attorney fees and costs) incurred through claims of third parties against LICENSOR based on the manufacture or sale of the Licensed
Products including, but not limited to, actions founded on product liability.

 

B. LICENSOR agrees to defend, indemnify and
hold LICENSEE and its officers, directors, agents, employees, and customers, harmless against all costs, expenses, and losses (including
reasonable attorney fees and costs) incurred through claims of third parties against LICENSEE based on a breach by LICENSOR of
any representation and warranty made in this Agreement, including but not limited to claims by a third party of infringement based
on the manufacture, use, or sale of items embodying the invention of the Patents.

 

13. INSURANCE

LICENSEE shall, throughout the Term of the
Agreement, obtain and maintain at its own cost and expense from a qualified insurance company licensed to do business in wherever
it operates and having a Moody’s rating of B+ or better, standard Product Liability Insurance naming LICENSOR, and its officers,
directors, employees, agents, and shareholders, as an additional insured. Such policy shall provide protection against all claims,
demands, and causes of action arising out of any defects or failure to perform, alleged or otherwise, of the 

    	5 of 7

    	 

    

 

Licensed Products
or any material used in connection therewith or any use thereof. The amount of coverage shall be as specified in Schedule A attached
hereto. The policy shall provide for 7 days’ notice to LICENSOR from the insurer by registered or certified mail, return
receipt requested, in the event of any modification, cancellation, or termination thereof. LICENSEE agrees to furnish LICENSOR
a certificate of insurance evidencing same within 7 days after execution of this Agreement and, in no event, shall LICENSEE manufacture,
distribute, or sell the Licensed Products prior to receipt by LICENSOR of such evidence of insurance.

 

14. NOTICE AND PAYMENT

A. Any notice required to be given under this
Agreement shall be in writing and delivered personally to the other designated party at the above stated address or mailed by certified,
registered or Express mail, return receipt requested or by Federal Express.

 

B. Either party may change the address to which
notice or payment is to be sent by written notice to the other under any provision of this paragraph.

 

15. JURISDICTION/DISPUTES

This Agreement shall be governed in accordance
with the laws of the State of Virginia. All disputes under this Agreement shall be resolved by litigation in the courts of the
State of Virginia including the federal courts therein and the Parties all consent to the jurisdiction of such courts, agree to
accept service of process by mail, and hereby waive any jurisdictional or venue defenses otherwise available to it.

 

16. AGREEMENT BINDING ON SUCCESSORS

The provisions of the Agreement shall be binding
upon and shall inure to the benefit of the Parties hereto, their heirs, administrators, successors and assigns.

 

17. ASSIGNABILITY

Neither party may assign this Agreement or
the rights and obligations thereunder to any third party without the prior express written approval of the other party which shall
not be unreasonably withheld.

 

18. WAIVER

No waiver by either party of any default shall
be deemed as a waiver of prior or subsequent default of the same of other provisions of this Agreement.

 

19. SEVERABILITY

If any term, clause or provision hereof is
held invalid or unenforceable by a court of competent jurisdiction, such invalidity shall not affect the validity or operation
of any other term, clause or provision and such invalid term, clause or provision shall be deemed to be severed from the Agreement.

 

20. INTEGRATION

This Agreement constitutes the entire understanding
of the Parties, and revokes and supersedes all prior agreements between the Parties and is intended as a final expression of their
Agreement. It shall not be modified 

    	6 of 7

    	 

    

 

or amended except in writing signed by the Parties hereto and specifically referring to this
Agreement. This Agreement shall take precedence over any other documents which may conflict with this Agreement.

 

21. Assignment - LICENSEE agrees to
purchase the Patents on or before December 31, 2023 and LISENSOR shall sell all rights to the Patents. The purchase price shall
be determined by an independent third party shall be based on the current market value of the patents and application in Schedule
A.

 

IN WITNESS WHEREOF, the Parties hereto, intending
to be legally bound hereby, have each caused to be affixed hereto its or his/her hand and seal the day indicated.

 

	Charles Scott	Survicore Financial Holdings, Inc

 

	By:	By:

 

		Title:

 

	Date:	Date:

 

 

Clinical & Herbal Innovations, Inc.

 

By:

 

Title:

 

Date:

    	7 of 7

    	 

    

 

 

 

 

SCHEDULE A

TO

LICENSE AGREEMENT

BETWEEN

Charles Scott and Survicore Financial Holdings,
Inc and Clinical & Herbal Innovations Inc

DATED 10/31/2018

 

 

1. Licensed Patents

The licensed Patents are as follows:

 

US Patent number 8,691,295 filed October 26, 2012

 

Philippines Application serial number 1-2014-500914

 

Canadian Application Serial Number 2889603

 

 

 

2. Licensed Products

The Licensed Products are as follows:

[Specify licensed
products.]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00289-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00289-of-00352.parquet"}]]